These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25708913)

  • 1. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
    Carmellini M; Garcia V; Wang Z; Vergara M; Russ G
    J Nephrol; 2015 Oct; 28(5):633-9. PubMed ID: 25708913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
    J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
    [No Abstract]   [Full Text] [Related]  

  • 7. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
    Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
    Cai L; Zeng F; Liu B; Wei L; Chen Z; Jiang J
    Int J Clin Pract Suppl; 2014 Apr; (181):23-30. PubMed ID: 24673716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
    Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
    Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study.
    Eisenberger U; Budde K; Lehner F; Sommerer C; Reinke P; Witzke O; Wüthrich RP; Stahl R; Heller K; Suwelack B; Mühlfeld A; Hauser IA; Nadalin S; Porstner M; Arns W;
    BMC Nephrol; 2018 Jun; 19(1):154. PubMed ID: 29954336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial.
    Colussi G; Vergara M; Wang Z; Roland R
    Clin Nephrol; 2015 Jun; 83(6):338-44. PubMed ID: 25816807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
    J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
    Chadban S; Eris J; Russ G; Campbell S; Chapman J; Pussell B; Trevillian P; Ierino F; Thomson N; Hutchison B; Irish A; Woodcock C; Kurstjens N; Walker R;
    Nephrology (Carlton); 2013 Jan; 18(1):63-70. PubMed ID: 23110508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
    de Fijter JW; Holdaas H; Øyen O; Sanders JS; Sundar S; Bemelman FJ; Sommerer C; Pascual J; Avihingsanon Y; Pongskul C; Oppenheimer F; Toselli L; Russ G; Wang Z; Lopez P; Kochuparampil J; Cruzado JM; van der Giet M;
    Am J Transplant; 2017 Jul; 17(7):1853-1867. PubMed ID: 28027625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.